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RED CELLS
Ribosomal protein S19 deficiency in zebrafish leads to developmental
abnormalities and defective erythropoiesis through activation of p53
protein family
Nadia Danilova,1 Kathleen M. Sakamoto,2,3 and Shuo Lin1
1Department of Molecular, Cell & Developmental Biology, University of California, Los Angeles (UCLA); 2Division of Hematology/Oncology, Department of
Pediatrics, Gwynne Hazen Cherry Memorial Laboratories and Mattel Children’s Hospital, Jonsson Comprehensive Cancer Center, David Geffen School of
Medicine at UCLA, Los Angeles, CA; and 3Division of Biology, California Institute of Technology, Pasadena
Mutations in several ribosomal proteins
(RPs) lead to Diamond-Blackfan anemia
(DBA), a syndrome characterized by de-
fective erythropoiesis, congenital anoma-
lies, and increased frequency of cancer.
RPS19 is the most frequently mutated RP
in DBA. RPS19 deficiency impairs ribo-
somal biogenesis, but how this leads to
DBA or cancer remains unknown. We
have found that rps19 deficiency in ze-
brafish results in hematopoietic and de-
velopmental abnormalities resembling
DBA. Our data suggest that the rps19-
deficient phenotype is mediated by dys-
regulation of deltaNp63 and p53. During
gastrulation, deltaNp63 is required for
specification of nonneural ectoderm and
its up-regulation suppresses neural differ-
entiation, thus contributing to brain/
craniofacial defects. In rps19-deficient em-
bryos, deltaNp63 is induced in erythroid
progenitors and may contribute to blood
defects. We have shown that suppression
of p53 and deltaNp63 alleviates the rps19-
deficient phenotypes. Mutations in other
ribosomal proteins, such as S8, S11, and
S18, also lead to up-regulation of p53
pathway, suggesting it is a common re-
sponse to ribosomal protein deficiency.
Our finding provides new insights into
pathogenesis of DBA. Ribosomal stress
syndromes represent a broader spectrum
of human congenital diseases caused by
genotoxic stress; therefore, imbalance of
p53 family members may become a new
target for therapeutics. (Blood. 2008;112:
5228-5237)
Introduction
The precise control of ribosome biogenesis and translation is
vital for cell survival. Cell growth and proliferation as well as
responses to genotoxic stress depend on ribosomal activity.
Defective ribosomal synthesis has been associated with bone
marrow failure syndromes, such as Diamond-Blackfan anemia
(DBA), dyskeratosis congenita, and Shwachman-Bodian-
Diamond syndrome.1 DBA is a congenital syndrome character-
ized by anemia, bone marrow erythroblastopenia, and increased
incidence of cancer.1-3 Anemia is often accompanied by growth
retardation and various malformations. Ribosomal protein S19
(RPS19) is mutated in one fourth of patients4; mutations of other
ribosomal proteins can also lead to DBA.5,6
Red blood cells of DBA patients manifest altered transcription,
translation, and activated apoptotic pathways.7-9 RPS19 is neces-
sary for ribosome biosynthesis. Certain RPS19 mutations affect its
structure and assembly into the ribosome.10,11 In yeast and human,
deficiency of RPS19 impairs the processing of 18S rRNA and
aberrant pre-40S particles are retained in the nucleolus.12-14 Nucleo-
lar organization is distorted in skin fibroblasts in all DBA patients
regardless of the presence of RPS19 mutations,13 suggesting that
defect in ribosome biogenesis is a general feature of DBA. The
nucleolus can act as a stress sensor; its disruption mediated p53
up-regulation.15 Mutations in other proteins participating in ribo-
some biogenesis lead to p53 up-regulation.16-18 Haploinsufficiency
of RPS6 and RPL22 also leads to activation of p53.19,20 Hence, we
hypothesized that up-regulation of p53 pathway is a common
response to ribosomal proteins deficiency and is involved in
molecular pathogenesis of DBA.
There is currently no animal model of DBA. In mouse, a
homozygous deletion of rps19 was lethal before implantation;
heterozygous mice, however, fully compensated for the loss of one
rps19 allele.21 Deficiency of RPS19 created in cell lines with RNAi
technology leads to cellular defects mimicking those in DBA.22
Nonetheless, cellular models cannot take into account the role of
RPS19 during development. DBA is a congenital disease, which
implies that the abnormal phenotype forms during early develop-
ment. Therefore, there is still a need for a true animal model to
understand the impact of RPS19 deficiency during embryogenesis.
To easily follow all developmental stages, it is advantageous to use
zebrafish. Antisense morpholino nucleotides have been success-
fully used in zebrafish to knockdown various genes.23 The use of
this technology for ribosomal genes including RPS19 has been
recently demonstrated.24
To this end, we created rps19-deficient zebrafish using antisense
morpholinos. In this model, we evaluated how RPS19 deficiency
affected early development. An advantage of the morpholino
knockdown approach is that a gradual change in RPS19 deficiency
can be achieved by changing the dose of injected morpholinos.
Similar to the human disease, rps19 deficiency in zebrafish leads to
failure of erythropoiesis and to developmental abnormalities. Our
data suggest that dysregulation of p53 family contributes to DBA.
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Methods
Use of zebrafish was approved by UCLAAnimal Committee.
RNA synthesis
cDNA corresponding to the coding region of RPS19 was amplified with
primers containing EcoRV and Spe1 sites, digested, and ligated into the
expression vector T3TS. Mutations R62Q were introduced using GeneTai-
lor Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA). Capped
RNA was prepared using the Message Machine kit (Ambion, Austin, TX).
RNA was purified using RNeasy kit (QIAGEN, Valencia, CA) and
dissolved in water at the concentration 100 ng/L.
Morpholinos
Sequences were: rps19 translation MO 5-cactgttacaccacctggcatcttg; splic-
ing MO 5-gcttccccgacctttcaaaagacaa; splicing MO, 5 bases mismatch:
5-gattcctcgaactctcaatagacaa; Np63 MO inhibitor of translation 5-
ttggtctccaggtacaacatattgg; p53 MO inhibitor of translation, 5-gcgccattgctt-
tgcaagaattg25 (Gene Tools, Corvallis, OR). Morpholinos were injected at
one cell stage.
Reverse-transcription polymerase chain reaction
Total RNA was prepared using Trizol (Invitrogen). cDNA was synthesized
by reverse transcription of 2 g of the total RNA with the random hexamer
primers. Polymerase chain reaction (PCR) primers sequences are shown in
Table S1 (available on the Blood website; see the Supplemental Materials
link at the top of the online article).
Flow cytometry
A total of 300 embryos (20 hours postfertilization [hpf]) expressing green
fluorescent protein (GFP) under the control of the gata1 promoter26 were
dechorionated with pronase and homogenized in cold phosphate-buffered
saline (PBS) adjusted to fish blood osmolarity by addition of 10% of water,
and containing 30% fetal bovine serum (FBS). They were washed twice and
incubated in the same buffer with 1 mg/mL collagenase/dispase (Roche
Diagnostics, Indianapolis, IN), 10 mg/mL trypsin, and 10 units/mL
DNAse1 at 30°C for 1 hour with agitation. Cells were washed twice, filtered
through a cell strainer, and suspended in the PBS/FBS with 1 g/mL DAPI
(46-Diamidino-2-phenylindole dihydrochloride (Roche Diagnostics) to
label dead cells. GFP-positive cells were sorted and collected to PBS/FBS.
In situ hybridization
Whole mount in situ hybridization was carried out as described.27 The
following riboprobes were used: globin e1,28 c-myb,29 lft2,30 pax2,31
gata2,32 insulin,33 Np63,34 and gsc.35
Results
Creating rps19-deficient zebrafish using morpholinos
RPS19 is highly conserved with 87.7% identity between zebrafish
and humans. Most residues that are mutated in DBA patients are
identical in the human and zebrafish. Similar to the human gene,
zebrafish rps19 has 6 exons, the first exon is untranslated, and the
start codon is located at the beginning of exon 2 (Figure 1A).
Zebrafish embryos start transcribing rps19 at approximately 6 hpf
but at a low level (Figure 1B). Eggs are supplied with maternal
ribosomes, and the embryo can proceed through initial developmen-
tal stages even if its own ribosome biosynthesis is blocked. The
expression of rps19 is gradually increased during the first day of
development.
To create deficiency of rps19, we designed morpholino MOs
blocking splicing of rps19 mRNA at exon 3 (Figure 1A). The effect
of MOs was monitored by RT-PCR. At 24 hpf, the amount of rps19
mRNA message was specifically, dose-dependently reduced in
embryos injected with the morpholino (Figure 1C). The reduction
in mRNA paralleled the viability of morphants (Figure 1D). rps19
mutations identified in DBA include allele deletion, internal
deletions, premature stop codons, and missense mutations, some of
which are inherited as dominant and some as recessive. Morpho-
lino knockdown most closely mimics allele deletion, although
splicing morpholino may lead to aberrant truncated messages
similar to premature stop codon mutations. After injection of 0.8 ng
MOs, we observed approximately 50% decrease of rps19 mRNA
level, similar to DBA. At a dose of 3.4 ng, only a trace amount of
mRNA is produced, and we used this dose to reveal the conse-
quences of rps19 deficiency at conditions harsher than in DBA.
This dose lets embryos survive up to 7 to 8 days. Some morpholi-
nos can cause off-target effects.36 To confirm specificity of our
morpholino, we designed another morpholino, MOt, blocking
translation of rps19. Injection of both morpholinos resulted in a
similar phenotype, and the simultaneous injection of 0.8 ng of MOs
Figure 1. Expression of rps19 in zebrafish embryos is specifically down-
regulated by an antisense morpholino. (A) Zebrafish rps19 gene is composed of 6
exons. Antisense morpholinos corresponding to the sequence around the transla-
tional start site in exon 2 are designed to inhibit translation. Morpholinos derived from
the intron 2 exon 3 boundary are designed to inhibit splicing. (B) Embryos start
synthesizing rps19 mRNA at approximately 6 hpf; the low amount of rps19 mRNA at
0 to 3 hours postfertilization (hpf) is of maternal origin. RNA was pooled from at least
30 embryos at each time point. (C) Morpholinos targeting the splicing site of exon 3 of
rps19 gene significantly decrease the level of rps19 mRNA message at 24 hpf:
RT-PCR.➔ in panel A show the positions of primers. Amounts of injected morpholino
per embryo are indicated. Actin expression is used as a load control. A total of 60 to
100 embryos were injected with each dose; RNA was prepared from at least
30 embryos. A result representative of 3 experiments is shown. (D) Survival of
zebrafish embryos depends on the dose of injected morpholinos. Complete blocking
of RPS19 expression at 5 ng per embryo leads to death of all embryos at 48 hpf. The
dose of 3.4 ng allows embryos to survive for approximately a week. Sixty to
100 embryos were injected with each dose, a representative experiment is shown.
(E) Ribosomal biogenesis is defective in morphants. At 30 hpf, the amount of rRNA is
lower in morphants. Total RNA was prepared from 30 wild-type or morphant embryos;
the amount of loaded RNA is equivalent to 4 embryos.
ZEBRAFISH MODEL OF DIAMOND-BLACKFAN ANEMIA 5229BLOOD, 15 DECEMBER 2008  VOLUME 112, NUMBER 13  personal use only.
For at CALIFORNIA INST TECH/MILLIKAN LIBRARY on December 10, 2008. www.bloodjournal.orgFrom 
and MOt had an additive effect approximately equal to the injection
of 5 ng of each morpholino (data not shown). As an additional
control, we designed a morpholino with 5 bases mismatch to MOs.
Its injection in doses 0.8 to 13 ng per embryo had no effects on
development (data not shown).
Ribosome biogenesis is impaired in DBA.12-14 In zebrafish
embryos, mutations of ribosomal proteins other than RPS19 also
result in a lower level of rRNA.37 The level of rRNA in our
morphants was lower than in wild-type fish at 30 hpf (Figure 1E).
Phenotype of rps19-deficient embryos
We compared the effects of rps19 deficiency in zebrafish with
clinical manifestations of DBA. Developmental defects are found
in approximately 40% of DBA patients with mutations in RPS19.
They include such dissimilar malformations as microcephaly and
macrocephaly, low ear set, small lower jaw, glaucoma, heart septal
defects, spine defects, kidney aplasia, and anogenital fistula.38
Short stature is frequently observed in DBA. Another trait is
duplication of thumbs and other structures. A particular defect can
be restricted to one side of the body, such as left kidney aplasia.
This feature suggests defective left-right patterning. Some patients
have multiple defects, whereas in others only erythropoiesis is
impaired. Indeed, individuals who are carriers for RPS19 mutations
may be asymptomatic. For example, an R94Stop identified in
2 sisters and their mother led to thumb malformations and
duplicated ureter in one sister and congenital glaucoma in the other
but had no effect in their mother.4 Thus, humans can compensate
for a defective RPS19 allele and other factors modulate the
phenotypic manifestation of the primary genetic defects.
Embryos injected with a low dose (0.8 ng) of morpholino,
which reduces the rps19 level by 50%, are morphologically normal
and have defects only in erythropoiesis. The phenotype of embryos
with higher rps19 deficiency resembled overall the phenotype
reported previously in zebrafish with overactivated p53 path-
way.25,36 The effect of morpholino injection was not apparent until
gastrulation, at which point a delay in the development of the
morphants was observed in comparison to noninjected embryos. It
may be that at this stage maternal ribosomes cannot fulfill the
embryo’s needs anymore, and it starts assembling its own ribo-
somes. Morphologic defects in morphants became evident during
somatogenesis. rps19-deficient embryos had reduced forebrain and
eye field as was revealed by in situ hybridization with pax2a probe
(Figure 2A,B). Anterior movement of ventral diencephalic precur-
sors, which separates the eye field into 2 bilateral eyes,39 is
defective in morphants. In a number of embryos, the eye field was
separated incompletely, resulting in defective eyes. At 18 to 24 hpf,
morphants had dark regions in their forebrain (Figure 2C,D). In 0%
to 5% of embryos, the forebrain and eyes were absent (Figure 2E).
Overall, rps19-deficient embryos are shorter than the wild-type and
have smaller head and eyes (Figure 2F) similar to the phenotype of
Drosophila ribosomal mutants Minute.40 Short stature is also a
common feature in DBA. Another feature resembling DBA is
sensitivity of zebrafish response to rps19 deficiency manifested
between different fish lines, between the progeny of different pairs,
and even between siblings (Figure 2G).
The dark regions in the forebrains of rps19-deficient embryos
suggest that the embryos had increased apoptosis. Apoptosis is a
part of normal development. Apoptotic cells appear in zebrafish
embryo at the tail bud stage, peak at approximately 17 hpf and
decline afterward, so that only few apoptotic cells are seen after
19 hpf. We visualized apoptotic cells by staining with the vital dye
acridine orange.41 In contrast to control embryos, apoptosis was
abundant at 20 hpf in morphants even when we used 0.8 ng
morpholino per embryo, a dose that did not lead to obvious
morphologic defects (Figure 2H,I).
At day 5, morphologic abnormalities became more evident in
morphants (Figure 2J-O). Their head cartilage had not formed
properly. Sometimes only rudiments of the jaw arches were
present, whereas posterior pharyngeal arches were completely
absent (Figure 2K,L). The head cartilage is formed by neural crest
cells. Defects in cartilage formation indicate that neural crest cells
could not form, migrate to their destinations, or proliferate.
Cartilage malformations varied between the embryos and gave
them diverse phenotypes (Figure 2K). Many morphants developed
edema pointing to cardiovascular or blood problems (Figure 2N).
Eyes are usually fully developed in zebrafish at day 5 but
morphants often had underdeveloped eyes, sometimes asymmetric.
In fish without forebrain, we noticed overgrowth of the fins
(Figure 2O).
Because asymmetric defects are common in DBA, we studied
left-right patterning in rps19-deficient embryos by analyzing the
expression of asymmetrically expressed genes. The lft2 gene is
expressed on the left side of the body in the heart field. In a fraction
of morphants, lft2 staining was found on the right side or medially
(Figure 2P,Q). During development, the heart undergoes looping to
the right from the atrium to the ventricle. In our sample, of
45 wild-type embryos 42 were right-looping and 3 were left
looping at 48 hpf, whereas of 37 of their rps19-deficient siblings,
24 were right looping, 9 were left looping, and 4 were nonlooping.
Reversed or bilateral position of visceral asymmetric organs, such
as pancreas, was also found in morphants. Pancreas localized by
staining with an insulin probe was found on the right side in
22 wild-type embryos. In their rps19-deficient siblings, 10 had
pancreas on the right side, 6 on the left side, 3 in the middle, and
one had bilateral dispersed staining (Figure 2R-T). This finding
indicates that rps19-deficient embryos exhibit cardiac and visceral
heterotaxia in agreement with the presence of asymmetric defects
in DBA patients. Abnormalities in left-right pattering can also
account for frequent cardiac septal defects described with DBA.
The rps19-deficient phenotype was rescued by injection of
zebrafish rps19 mRNA (Figure 2U). In the group coinjected with
MOs and mRNA, the whole phenotypic spectrum shifted in
comparison to the group receiving only the morpholino. The
number of embryos with normal morphology at 48 hpf increased
from the average 7.3% to 35%, the number of embryos with serious
defects dropped from 41% to 16%, and the death rate decreased
from 24% to 10%. These changes clearly illustrate the specificity of
the phenotype. No rescue was observed after injection of mRNA
encoding GFP protein. Next, we questioned whether RPS19
mRNA could rescue embryos injected with the translation-
inhibiting morpholino. Zebrafish rps19 mRNA cannot be used for
this purpose because its translation would be blocked by the
morpholino. We therefore synthesized a human RPS19 mRNA. It is
only approximately 50% identical to the zebrafish mRNA in
nucleotide sequence around the initiation site, and its translation,
therefore, cannot be blocked by MOt. Injection of the human
mRNA rescued rps19 deficiency caused by MOt. In embryos
injected with 3.4 ng of MOt, 20% had normal morphology, 28%
had mild defects, 15% had severe defects, and 37% were dead at
48 hpf. In embryos coinjected with MOt and human RPS19
mRNA, the corresponding numbers were 42/34/3/21.
To determine whether introduction of a missense mutation into
rps19 would cause a phenotype similar to that of rps19 down-
regulation, we injected embryos with 200 to 400 pg of zebrafish or
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human RPS19 mRNA carrying R62/Q mutation, typical in DBA.
We observed, in approximately 25% of embryos, phenotypic
changes similar to those observed in rps19-deficient embryos, such
as shortening of the body and craniofacial defects although milder
than in rps19-deficient fish (data not shown). These results are in
accord with human data that various types of RPS19 mutations lead
to a similar phenotype.
Erythropoiesis is compromised in rps19-deficient zebrafish
The hallmark of the DBA syndrome is deficiency of hematopoietic
progenitors, in particular, of the erythroid lineage. Many patients
are diagnosed with anemia at birth or within the first year of life,
which suggests an early onset of erythropoietic defects. Similar to
other vertebrates, the zebrafish experiences 2 waves of blood
formation: primitive, producing erythrocytes and macrophages;
and definitive, producing all blood lineages.32 Zebrafish rps19-
deficient embryos have normal or slightly increased expression of
gata1 in blood progenitors at 18 hpf (data not shown). Erythroid
progenitors proliferate and differentiate into mature erythrocytes in
the intermediate cell mass (ICM), a region between the dorsal aorta
and axial vein. We injected rps19 morpholino into transgenic
zebrafish expressing GFP protein under the control of the gata1
promoter26 and, at 20 hpf, sorted the GFP-expressing cells from
controls and morphants. Approximately 3% of cells in control
embryos were GFP-positive, whereas in RPS19-deficient siblings
2% were GFP-positive, which may indicate a lower rate of
proliferation in cells committed to erythroid lineage in morphants.
The expression of the globin e3 was lower in morphant cells, also
indicating a defect in erythroid lineage (Figure 3A). Circulation
establishes in zebrafish at approximately 24 hpf, when cells leave
the ICM. In morphants, however, more red cell progenitors
remained in the ICM as evidenced by in situ hybridization with
globin e1 probe (Figure 3B). This effect was dose-dependent; the
higher the dose of the morpholino, the fewer erythroid cells entered
the circulation. At higher doses, where cardiac and other defects are
common, this effect could be partially explained by circulation
defects, but it is observed even in embryos without morphologic
defects injected with 0.8 ng of morpholino. C-myb is highly
expressed in erythroid progenitors; and when erythrocytes mature,
c-myb expression declines. In morphants, however, cells continued
to express c-myb. These features suggest that differentiation of
erythroid lineage was defective in morphants (Figure 3C).
Figure 2. Phenotype of rps19-deficient embryos. (A,B) Forebrain (➔) and eye field (‹) are reduced in morphants. In situ hybridization, pax2a probe, 16 hpf. In situ
hybridization was performed on 30 morphant or wild-type embryos. (C,D) At 24 hpf, morphants have small head and eyes, pinched midbrain-hindbrain boundary, and necrotic
regions in brain (➤). A typical morphant embryo is shown. (E) In some morphants, forebrain and eyes are absent. The frequency of this phenotype was 0% to 5%. (F)
rps19-deficient embryos are smaller than wild-type. (G) Phenotypic manifestations of rps19 deficiency vary between the progeny of different pairs. Red represents normal
looking; yellow, mild malformations; blue, strong malformations; purple, forebrain and eyes are absent; violet, dead. Twenty-five healthy looking morphants from each pair were
selected at 6 hpf and compared at 20 hpf. Progeny of 4 pairs are shown as an example. (H,I) The level of apoptosis is higher in morphants. Acridine orange staining,
1 g/mL, 30 minutes, 20 hpf. A representative embryo from at least 30 is shown. (J-L) Cartilage of the head is malformed in morphants. Alcian blue, 120 hpf. (M-O) The
morphant fish shown in panel N has edema (➔); eyes are present but abnormal. The fish shown in panel O has no eyes and forebrain. Note an abnormally large ventral fin in
this fish, 120 hpf. (P,Q) Heart field’s position and orientation are reversed in some morphants. In situ hybridization, lft2 probe, 19 hpf. An embryo representative of the group of
30 embryos used for in situ hybridization is shown. (R-T) Position of visceral organs is also randomized in morphants. Pancreas is located on the right side in wild-type fish (R),
whereas in some morphants it is on the left (S) or bilateral. (T) 120 hpf, insulin probe. (U) rps19-deficient embryos are rescued by injection of 200 pg of rps19 mRNA. The
proportion of normal-looking embryos among RPS19-deficient morphants is higher in the group injected with the RNA; the proportion of embryos with severe defects is reduced
as is the death rate. No effect was observed after injection of GFP mRNA: 48 hpf, 3.4 ng MOs/embryo. Red represents morphologically normal embryos; yellow, mild defects;
blue, severe defects; black, death. Eighty embryos were used per group. Shown are the results representative of 3 independent experiments.
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The development of the definitive wave of erythrocytes in
rps19-deficient embryos was also impaired. During normal devel-
opment, primitive erythrocytes stay in circulation for several days
to be replaced by adult-type cells starting from days 4 to 5.
Zebrafish adult-type erythrocytes start to develop from approxi-
mately 24 hpf in the region of the dorsal aorta. They then migrate to
the caudal region where they proliferate and differentiate before
entering the circulation.42 It seems that in morphants primitive cells
were eliminated from circulation, but they were not replaced by
adult-type erythrocytes and the total number of cells in circulation
gradually dropped to very low numbers (Figure 3D). Erythroid
precursors appeared to be present in rps19-deficient embryos but
did not mature and were retained in the tail blood island. This
pattern again points to differentiation defect in these embryos.
Morphologically, erythrocytes from morphants differed from wild-
type cells at day 5 (Figure 3E). They varied in size and some cells
retained a blastlike phenotype. Immature erythrocytes in rps19-
deficient embryos are reminiscent of that of DBA patients, in which
the cells have higher mean corpuscular volume. The level of
hemoglobin is decreased in DBA patients; therefore, we analyzed
hemoglobin levels in morphants. We used MOs doses that caused
no (0.8 ng) or few (2.5 ng) morphologic abnormalities. We found
that the hemoglobin level was decreased even after injection of
0.8 ng of MOs (Figure 3F). These findings indicate that rps19
deficiency in zebrafish results in defective proliferation and differ-
entiation of erythroid progenitors similar to that found in humans.
The development of other blood lineages was less affected in
morphants. The expressions of myeloid and lymphoid markers do
not significantly differ between wild-type and rps19-deficient
embryos (Figure S1).
p53 network up-regulation in rps19-deficient embryos
In our morphants, we observed headless phenotype in the progeny
of some fish pairs. Partial loss of the forebrain was previously noted
in zebrafish after forced overexpression of zebrafish and human
p53 and p73.43 Interestingly, this phenotype is also observed after
overexpression of Np63.34 In the latter case, the headless
phenotype was rescued by coinjection of p53 mRNA. These data
indicate that headless phenotype can be caused by p53/Np63
imbalance regardless of the absolute amount of these messages.
Therefore, we analyzed the expression of p53 family genes in
RPS19-deficient embryos. p53, p63, and p73 are expressed as
full-length isoforms, capable of inducing cell-cycle arrest and
apoptosis or as N-terminally truncated isoforms acting as dominant-
negative regulators of the full-length proteins44 (Figure 4A).
Complex regulatory loops connect the full-length and dominant-
negative isoforms. At some conditions, p53 drives the expression
of its inhibitor, Np63, and down-regulation of p53 abolishes the
expression of Np63.45 On the other hand, p53 can associate with
Np63 and target it to degradation.46 Both members of this loop
receive inputs from other pathways. Specifically, Np63 is stimu-
lated by growth factors,47 whereas in response to some genotoxic
stressors it mediates silencing of its own promoter.45 UV irradiation
results in up-regulation of p53 but down-regulation of Np63.
Therefore, p53 network in a developing organism experiencing
stress would receive contradicting inputs.
We have found that rps19 deficiency induced by MOs changes
the transcription of p53 family (Figure 4B). Both full-length and
truncated p53 was up-regulated in rps19-deficient embryos but
with different dynamics. Transcriptional activation of full-length
Figure 3. RPS19-deficient embryos have defects in erythropoiesis. (A) RT-PCR, red blood progenitors sorted out from embryos at 19 to 20 hpf. Globin expression is lower
in morphants. The cells were purified from a pool of 300 embryos. (B) The differentiation of erythroid cells is delayed in morphants: at 30 hpf almost all erythroid cells are still in
ICM region in morphants. In situ hybridization, globin e1 probe, 30 hpf, 30 embryos per group. (C) Expression of c-myb in the tail regions in morphants (➔) points to immaturity
of red blood cells in these embryos. In situ hybridization, 30 hpf. (D) At 72 hpf, there are fewer blood cells in morphants; they are localized mostly in the posterior of the embryo
(➔), and there are only few cells in the heart region: 2.5 ng morpholino per embryo, O-dianizidine staining, 30 embryos per group. (E) Erythroid cells from the blood of a
morphant embryo are variable in size; some look like erythroblasts (➔). Zebrafish erythrocytes differ from mammalian cells in that both primitive and definitive cells are
nucleated. Blood smears were prepared from individual embryos; the results are representative of 6 to 10 embryos. (F) The level of hemoglobin is lower in morphants at day 5 in
dependence with morpholino dose. Hemoglobin levels were measured in pools of 80 embryos in triplicates. Five-day-old embryos (wild-type, morphants, or cloche mutants,
which have no blood cells) were homogenized in 500 L of Drabkin reagent (Sigma-Aldrich, St Louis, MO), incubated for 1 hour at room temperature, centrifuged 10 minutes at
16 000g, and the absorbance of supernatants was measured at 540 nm. Absorbance of cloche mutants was subtracted from the wild-type and morphant samples. In this way,
only the absorbance derived from red blood cells was taken into consideration. It was plotted on a calibration curve obtained from a standard sample with known concentration
of hemoglobin (Drew Scientific, Dallas, TX), and the amount of hemoglobin per embryo was calculated.
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p53 peaked around 18 to 24 hpf. A truncated form of p53,
113Np53, followed p53 up-regulation with a delay and remained
strongly up-regulated until 96 hpf. Overexpression of this isoform
has previously been shown to have no obvious effects on develop-
ment.36 In zebrafish embryos, p63 has only been found in the
truncated form, Np63. It plays a crucial role in specification of
nonneural ectoderm during gastrulation and in development of
epidermis and its derivatives.34,48 p73 in zebrafish embryos has
only been found in the full-length form, TAp73, expressed in a
restricted pattern in olfactory and other tissues.49 In RPS19-
deficient embryos, Np63 up-regulation, although lower and less
consistent than 113Np53 up-regulation, was detected from 18 to
24 hpf. Full-length p73 was up-regulated during the first day of
development. Other isoforms of p63 and p73 were not detected, in
accord with previous reports. Up-regulation of p73 was modest in
comparison to p53 and probably does not contribute much to p53
effects. The expression of p53 targets, such as p21 responsible for
induction of cell-cycle arrest and bax, a mediator of apoptosis,
followed the pattern of p53 expression. The expression of ada
enzyme, a target of p63/Np63,50 followed the pattern of Np63
expression. In human DBA, ADA is up-regulated in erythrocytes of
approximately 80% of patients.38 In embryos injected with MOt,
we also found up-regulation of p53 (Figure 4C), which confirms
that the observed effect is a specific response to rps19 deficiency.
In red blood cell progenitors, purified from embryos, p53 was
modestly up-regulated, whereas Np63 up-regulation was more
dramatic (Figure 4D). Overexpression of p53 increases cell sensi-
tivity to apoptosis, whereas Np63 overexpression supports prolif-
eration vs differentiation. Imbalance between p53 and Np63 may
affect the ability of blood cell progenitors to proliferate and
differentiate into erythrocytes.
Our findings show that ribosomal stress resulting from RPS19
deficiency in zebrafish leads to up-regulation of p53 network. To
verify our hypothesis that up-regulation of p53 family may be a
common response to ribosomal protein deficiency, we examined
expression of p53 family genes in zebrafish with mutations in rps8,
rps11, and rps18, which have been recently reported among other
RP mutations, all having similar phenotypes.51 We found a pattern
of p53 family protein expression in these mutants similar to rps19
morphants. Specifically, p53, 113p53, as well as p53 targets p21
and bax were strongly up-regulated in mutants at 22 hpf (Figure
S2) with modest up-regulation of TAp53, Np63, and p73 (1.5
times). Up-regulation was also observed in siblings, a mixture of
wild-type (33%) and heterozygous for RP mutations fish (67%).
Role of Np63 dysregulation
It is known that Np63 overexpression during gastrulation leads to
expansion of nonneural ectoderm and suppression of neural
structures.34 Because a fraction of rps19 morphant phenotype
resembled that of Np63 overexpression, we questioned whether
morphants also had expansion of nonneural ectoderm during
gastrulation. We did not detect increase in the expression of Np63
at 80% epiboly by RT-PCR, but by in situ hybridization with
Np63 probe we found an expansion of the area of Np63
expression in approximately 25% of morphants (Figure 5). In
wild-type embryos, Np63 expression is localized in the ventral
side of the embryo, whereas in this fraction of morphants, Np63
positive area is expanded to the dorsal side. This expansion
corresponded to the expansion of nonneural ectoderm into the
neural field as confirmed by hybridization with a marker of
nonneural ectoderm gata2. Shrinkage of the neural field affects the
eye and forebrain more than other structures. This may explain why
in RPS19-deficient embryos the forebrain is reduced. Suppression
of the neural field can affect all aspects of neurogenesis from
formation of the neural tube and ventricles to neural crest cells
development and migration. In our morphants, reduction of the
forebrain was observed in the progeny of not all fish pairs and it
differed between fish lines. It could be that up-regulation of p53
causes disproportional up-regulation of Np63 only in a particular
genetic background. Later in development during limb formation,
Np63 is expressed in epidermal stem cells in the apical ectoder-
mal ridge and its up-regulation may explain the overgrowth of
epidermal derivatives, such as enlarged fins in zebrafish and
perhaps extra digits in humans.
Alleviation of rps19-deficient phenotype by down-regulation of
p53 and Np63
Given that rps19-deficient phenotype is partially mediated by p53
pathway up-regulation, one could expect alleviation of the pheno-
type with down-regulation of p53. Indeed, when we injected
p53/ zebrafish embryos with a lethal dose of 3.4 ng rps19 MOs,
reducing rps19 mRNA level by more than 90%, morphants were
smaller than wild-type embryos but had no obvious morphologic
Figure 4. p53 family expression is dysregulated in rps19-deficient zebrafish. (A)
Proteins of the p53 family have similar structure. They are expressed as full-length
protein or truncated isoforms lacking all (113p53) or most part of transactivation
domain (Np63 and Np73). p63 and p73 can also be alternatively spliced at the C
end. Np63 and Np73 can inhibit all full-length p53 family members. (B) Expression
of p53 network genes in whole embryos received 3.4 ng of splicing blocking
morpholino at different time points. RT-PCR, RNA was pooled from 30 embryos. W
indicates wild-type; M, morphant embryos. (C) p53 is transcriptionally up-regulated in
embryos injected with 3.4 ng of MOt morpholino inhibiting rps19 translation: RT-PCR.
(D) p53 is up-regulated in red blood cell purified from 20 hpf embryos (pool of 300
embryos). Np63 is not expressed in wild-type but induced in morphant cells. ADA is
slightly up-regulated in morphant cells. Vertical lines have been inserted to indicate a
repositioned gel lane.
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defects and no neural apoptosis at day 1 (Figure S3). These
embryos survived approximately 4 days longer than the regular
morphants. Some of them, however, developed edema by day 5,
suggesting a shortage of erythroid cells. A lower dose of MOs
(0.8 ng) that resulted in 50% reduction of rps19 mRNA had no
effect on the phenotype and survival of p53/ zebrafish
embryos, suggesting that they compensated fully for rps19
deficiency of this magnitude (data not shown). Down-regulation
of p53 by injection of 3 ng/embryo of p53 antisense morpholino
as in the earlier reports,25 also improved the morphants’ survival
rates and phenotype (data not shown). We noticed that down-
regulation of p53 led to coordinated down-regulation of Np63,
which might be responsible for the rescue of forebrain develop-
ment in fish deficient both in rps19 and p53 (Figure 6A).
Interestingly, a lower (1.2 ng) dose of p53 morpholino acted
synergistically with 0.4 to 0.8 ng morpholino targeting
Np63 in alleviating the morphant phenotype (Figure 6B),
whereas injected alone Np63 morpholino led to a stronger
up-regulation of p53 and to increase in the death rate at 24 hpf.
These data illustrate again that the right balance of the
p53-Np63 loop is important for normal development.
We next questioned whether compounds inhibiting p53 path-
way can improve the phenotype and survival of rps19-deficient
zebrafish. Pifithrin  inhibits p53 binding to mitochondria by
reducing its affinity to antiapoptotic proteins Bcl-xL and Bcl-2.52 It
specifically suppresses the mitochondria branch of the p53 pathway
but does not affect other p53 functions. We found that pifithrin 
had no effect of the p53 mRNA level in zebrafish embryos but was
efficient in improving rps19-deficient phenotype (Figure 6C).
These data suggest that suppression of p53 activity might be a new
direction for development of novel drugs for DBA treatment.
Discussion
Zebrafish response to rps19 deficiency has many features of DBA,
including impaired ribosome biogenesis, increased apoptosis, devel-
opmental abnormalities, and defective hematopoiesis. It is accom-
panied by up-regulation of p53 family. Such up-regulation may
result from the distortion of nucleolar organization reported in
RPS19 deficiency,13 which may lead to p53 activation.15,53 On the
other hand, several ribosomal proteins can activate p53 through
inhibition of MDM2-mediated ubiquitination,54 which makes it
probably that several pathways converge on p53. We observed
up-regulation of p53 pathway not only in rps19 morphants but also
in rps8, rps11, and rps18 mutants. Similar to rps19 and many other
RPs, Rps8, Rps11, and Rps18 are necessary for pre-rRNA process-
ing.55 These data suggest that up-regulation of p53 pathway may be
a common response to deficiency of essential ribosomal proteins.
Figure 5. Np63 dysregulation contributes to the rps19-deficient phenotype.
Nonneural ectoderm (➔) is expanded in rps19-deficient embryos at the expense of
neural one (Š). In situ hybridization with p63 and gata2 probes. Hybridization with gsc
probe (red arrow) was used to mark the dorsal side. Tilted dorsal view. Thirty
wild-type or morphant embryos were used in the reaction; 7 or 8 from the morphant
group had visible expansion of the nonneural ectoderm markers. Representative
embryos are shown. Schema of zebrafish fate map at 6 hpf shows side view.
Figure 6. Down-regulation of p53 and Np63 alleviates rps19-deficient pheno-
type. (A) p53 and Np63 regulate each other expression. Expression of Np63 is
decreased in rps19-deficient embryo injected with 8 ng of p53-specific morpholi-
nos. On the contrary, expression of p53 in RPS19-deficient embryo injected with
high dose (8 ng/embryo) of Np63-specific morpholino is increased. RNA was
prepared from 30 embryos at each time point. (B) Coinjection of low doses of
p53-specific and Np63-specific morpholinos increases the number of morphologi-
cally normal embryos among morphants. Eighty embryos were injected in each
group. A result representative of 3 independent experiments is shown. (C)
Pharmacologic inhibition of p53 pathway by a small molecule pifithrin  improves
phenotype of rps19-deficient embryos. Eighty injected embryos were used for the
control and experimental group.
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p53 family is instrumental in development for control of
proliferation and differentiation. p53 has been implicated in
suppression of stem cells renewal and promotion of differentia-
tion.56 On the other hand, N isoforms can be directly regulated
by growth factors and support proliferation.47,57 Our data
illustrate that a fine balance between p53 and the Np63 is
required for proper development. In blood cell progenitors,
which have a high rate of proliferation, the pattern of p53 family
activation differs from the whole embryo as indicated by a
stronger activation of Np63 than p53. Therefore, differential
regulation of p53 and delta isoforms may depend on tissue type
and extracellular signals (Figure 7).
The importance of p63 in development is well recog-
nized. Deficiency of p63 in humans results in developmental
defects characterized by limb malformations, orofacial clefts,
and ectodermal dysplasia.58 Less attention has been paid to the
effect of p63 overactivation. It may have a dual signature.
Suppression of the neural field during gastrulation could affect
the eye, brain, and neural crest derivatives. Overexpression of
p63 at the stage when epidermal appendages are formed
would most probably be manifested in duplication of structures,
such as digits.
p63 up-regulation in erythroid progenitors may keep
them in a nondifferentiated state. p63 is a BMP4 target and
BMP4 regulates the expansion of the erythroid progenitors
termed stress-BFU-E in response to acute anemia.59 One
possibility is that in response to ribosomal stress BMP4-Np63
pathway is activated constitutively. Downstream targets of
p63 include Shh60 and continuous SH activation leads to
hematopoietic stem cells exhaustion.61 Therefore, Np63 may
contribute to the RPS19-deficient blood phenotype in zebrafish
and human. Overexpression of Np63 increases growth of
transformed cells,62 which may contribute to high risk of
hematopoietic malignancies in DBA.
The p53 family network is very complex with hundreds of
proteins involved. It may explain variable penetrance and expressiv-
ity of RPS19-deficient phenotype. Both environmental and genetic
factors may modulate phenotypic manifestations. We observed, for
example, that if rps19-deficient zebrafish embryos developed at
room temperature instead of 28°C, the phenotype was less pen-
etrant. Genetic background may significantly influence the p53
network. It is known that some strains of p53/ mice are normal
developmentally,63 whereas in other strains, females have brain
overgrowth, extra digits, and eye defects.64,65
Dysregulation of p53 family may be a mechanism underlying
many congenital abnormalities. The p53 family monitors all crucial
cellular processes. Defects in genes responsible for ribosomal
biogenesis, chromatin maintenance, DNA repair, RNA splicing,
metabolism, destruction of oxygen species, protein folding, and
other processes can potentially trigger p53 pathway as has been
already demonstrated for some genes.16,17,66,67 The generality of
this phenomenon may be underestimated. Excessive neural cell
death was observed in more than half of mutants found in a recent
mutagenic screen, most of them in the aforementioned categories.51
Neural cell death and “off-target” p53 activation have been
reported in more than 20% of cases in knockdown technologies,
such as morpholino or RNAi.36 Developmental phenotypes result-
ing from p53-mediated generalized stress response would depend
on a development stage, when a deficiency of a particular gene
triggers stress response. If stress occurs early in gastrulation, global
defects in establishment of body axis or neural system patterning
are probable. On the other hand, when the affected gene is
expressed later in development, the defects may be milder.
In conclusion, our data together with previous findings suggest
that many human congenital syndromes, probably a majority of
them, develop not according to the linear scheme, a gene defect
causes certain downstream phenotype, but according to a more
systemic process, where defects in multiple genes can trigger the
same master network leading to a spectrum of cognate abnormal
phenotypes. Excessive activity of p53 and imbalance between p53
family members may be an underlying cause of many developmen-
tal anomalies in humans. Strong modulation of a phenotype by the
genetic background may be a hallmark of p53 family-dependent
disorders, taking into account the number of genes involved in the
p53 network. New approaches to treatment and prevention of such
diseases may involve the p53 family.
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